On September 13, 2019 an FDA advisory board recommended approval of an oral peanut vaccine (\u201cOIT\u201d for oral immunotherapy).\u00a0 If this recommendation leads to approval, peanut allergic individuals will be faced with a tough decision.<\/p>\n
Approval is based in part on large studies done in California on children and adults with severe peanut allergy.\u00a0 In this study, 85% of the OIT treated patients were able to tolerate 4 grams of peanut without serious reaction.\u00a0 That\u2019s the good news.<\/p>\n
The bad news is that stopping OIT lead to a fairly quick return of the severe allergy.\u00a0 Additional bad news is that despite being protected from severe reactions a large number of patients had frequent mild allergic reactions and were prone to develop a condition called eosinophilic esophagitis \u2013 a form of allergic reflux.<\/p>\n","protected":false},"excerpt":{"rendered":"
On September 13, 2019 an FDA advisory board recommended approval of an oral peanut vaccine (\u201cOIT\u201d for oral immunotherapy).\u00a0 If this recommendation leads to approval, peanut allergic individuals will be faced with a tough decision. Approval is based in part on large studies done in California on children and adults with severe peanut allergy.\u00a0 In this study, 85% of the OIT treated patients were able to tolerate 4 grams of peanut without serious reaction.\u00a0 That\u2019s the good news. The bad…<\/p>\n